NEW YORK (GenomeWeb News) - Biomax Informatics said this week that it has been selected as a consortium partner in Austria’s OncoTyrol project Center for Personalized Cancer Medicine.

 

The four-year, €28 million ($43.7 million) OncoTyrol initiative focuses on “translating genomic, proteomic and metabolomic research into innovative, individualized, and cost-effective approaches for cancer diagnosis and treatment,” Biomax said.